Inovio (INO) announced that a second patient with HPV-related head and neck cancer treated with INO-3112 in a Phase 1 trial achieved a sustained complete response, full remission, after subsequent treatment with a PD-1 checkpoint inhibitor. This marks the second patient with metastatic cancer observed in full remission after treatment with synthetic DNA vaccine followed by a PD-1 checkpoint inhibitor. Of the four patients who developed progressive disease and were subsequently administered a PD-1 checkpoint inhibitor, two patients rapidly exhibited a complete response. The most recent patient for which data was presented yesterday received pembrolizumab, or Keytruda; while the previously reported complete responder was treated with nivolumab, or Opdivo. The patients moved from metastatic head and neck cancer to no evidence of disease and they remain alive two years after treatment. Keytruda is a registered trademark of Merck (MRK); Opdivo is a registered trademark of Bristol-Myers Squibb (BMY).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.